Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout the body:

Read more at globenewswire.com